JP2020524519A - 全セルフリーdnaによる移植合併症リスクの評価 - Google Patents

全セルフリーdnaによる移植合併症リスクの評価 Download PDF

Info

Publication number
JP2020524519A
JP2020524519A JP2019571052A JP2019571052A JP2020524519A JP 2020524519 A JP2020524519 A JP 2020524519A JP 2019571052 A JP2019571052 A JP 2019571052A JP 2019571052 A JP2019571052 A JP 2019571052A JP 2020524519 A JP2020524519 A JP 2020524519A
Authority
JP
Japan
Prior art keywords
dna
amount
total
subject
transplant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019571052A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020524519A5 (https=
Inventor
ミッチェル,アオイ,トミタ
ミッチェル,ミカエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical College of Wisconsin
Original Assignee
Medical College of Wisconsin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical College of Wisconsin filed Critical Medical College of Wisconsin
Publication of JP2020524519A publication Critical patent/JP2020524519A/ja
Publication of JP2020524519A5 publication Critical patent/JP2020524519A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6858Allele-specific amplification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6851Quantitative amplification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/101Sanger sequencing method, i.e. oligonucleotide sequencing using primer elongation and dideoxynucleotides as chain terminators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2019571052A 2017-06-20 2018-06-20 全セルフリーdnaによる移植合併症リスクの評価 Pending JP2020524519A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762522533P 2017-06-20 2017-06-20
US62/522,533 2017-06-20
US201762572556P 2017-10-15 2017-10-15
US62/572,556 2017-10-15
PCT/US2018/038598 WO2018237075A1 (en) 2017-06-20 2018-06-20 Assessing transplant complication risk with total cell-free dna

Publications (2)

Publication Number Publication Date
JP2020524519A true JP2020524519A (ja) 2020-08-20
JP2020524519A5 JP2020524519A5 (https=) 2021-07-29

Family

ID=64735781

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019571052A Pending JP2020524519A (ja) 2017-06-20 2018-06-20 全セルフリーdnaによる移植合併症リスクの評価

Country Status (8)

Country Link
US (2) US11773434B2 (https=)
EP (2) EP3642353B1 (https=)
JP (1) JP2020524519A (https=)
CN (1) CN110945136A (https=)
AU (2) AU2018288832B2 (https=)
CA (1) CA3067637A1 (https=)
IL (1) IL271460A (https=)
WO (1) WO2018237075A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9424392B2 (en) 2005-11-26 2016-08-23 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
US11111544B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US11111543B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US9677118B2 (en) 2014-04-21 2017-06-13 Natera, Inc. Methods for simultaneous amplification of target loci
WO2011146632A1 (en) 2010-05-18 2011-11-24 Gene Security Network Inc. Methods for non-invasive prenatal ploidy calling
US11332785B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US12221653B2 (en) 2010-05-18 2025-02-11 Natera, Inc. Methods for simultaneous amplification of target loci
US11408031B2 (en) 2010-05-18 2022-08-09 Natera, Inc. Methods for non-invasive prenatal paternity testing
US11339429B2 (en) 2010-05-18 2022-05-24 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
US11332793B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for simultaneous amplification of target loci
US12152275B2 (en) 2010-05-18 2024-11-26 Natera, Inc. Methods for non-invasive prenatal ploidy calling
CN103608466B (zh) 2010-12-22 2020-09-18 纳特拉公司 非侵入性产前亲子鉴定方法
RU2671980C2 (ru) 2011-02-09 2018-11-08 Натера, Инк. Способы неинвазивного пренатального установления плоидности
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
CA2945962C (en) 2014-04-21 2023-08-29 Natera, Inc. Detecting mutations and ploidy in chromosomal segments
US20180173846A1 (en) 2014-06-05 2018-06-21 Natera, Inc. Systems and Methods for Detection of Aneuploidy
US11479812B2 (en) 2015-05-11 2022-10-25 Natera, Inc. Methods and compositions for determining ploidy
RU2760913C2 (ru) 2016-04-15 2021-12-01 Натера, Инк. Способы выявления рака легкого
WO2018067517A1 (en) 2016-10-04 2018-04-12 Natera, Inc. Methods for characterizing copy number variation using proximity-litigation sequencing
GB201618485D0 (en) 2016-11-02 2016-12-14 Ucl Business Plc Method of detecting tumour recurrence
US10011870B2 (en) 2016-12-07 2018-07-03 Natera, Inc. Compositions and methods for identifying nucleic acid molecules
US12084720B2 (en) 2017-12-14 2024-09-10 Natera, Inc. Assessing graft suitability for transplantation
US12024738B2 (en) 2018-04-14 2024-07-02 Natera, Inc. Methods for cancer detection and monitoring
US12234509B2 (en) 2018-07-03 2025-02-25 Natera, Inc. Methods for detection of donor-derived cell-free DNA
WO2020206290A1 (en) * 2019-04-03 2020-10-08 The Medical College Of Wisconsin, Inc. Methods for assessing risk using total cell-free dna
US11931674B2 (en) 2019-04-04 2024-03-19 Natera, Inc. Materials and methods for processing blood samples
US12305235B2 (en) 2019-06-06 2025-05-20 Natera, Inc. Methods for detecting immune cell DNA and monitoring immune system
CN111667883B (zh) * 2020-06-03 2021-01-22 四川大学 一种基于复合微单倍型焦磷酸测序图谱解析的法医学混合dna的分析方法
US20230399697A1 (en) * 2020-11-09 2023-12-14 The Medical College Of Wisconsin, Inc. Assessing risk with pre-operative total cell-free dna
WO2025079958A1 (ko) * 2023-10-11 2025-04-17 고려대학교 산학협력단 높은 처리량의 돌연변이 특이적 아답터 리게이션 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150086477A1 (en) * 2012-04-19 2015-03-26 Medical College Of Wisconsin, Inc. Highly sensitive surveillance using detection of cell free dna
WO2016176662A1 (en) * 2015-04-30 2016-11-03 Medical College Of Wisconsin, Inc. Multiplexed optimized mismatch amplification (moma)-real time pcr for assessing cell-free dna

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5319071A (en) 1987-11-25 1994-06-07 Immunex Corporation Soluble interleukin-1 receptors
WO1989004838A1 (en) 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
US5645988A (en) 1991-05-08 1997-07-08 The United States Of America As Represented By The Department Of Health And Human Services Methods of identifying drugs with selective effects against cancer cells
US5569582A (en) 1991-07-15 1996-10-29 Institute Of Molecular Biology & Technology Rapid amplification and detection of nucleic acids
PE64396A1 (es) 1995-01-23 1997-01-28 Hoffmann La Roche Proteina accesoria del receptor de la interleucina 1
CA2318030C (en) 1998-01-23 2009-02-17 Immunex Corporation Acpl dna and polypeptides
US20030148301A1 (en) 1999-12-10 2003-08-07 Toshiya Aono Method of detecting nucleotide polymorphism
EP1325963B1 (en) 2001-12-24 2006-09-27 Wolfgang Prof. Holzgreve Method for non-invasive diagnosis of transplantations and transfusions
US6977162B2 (en) 2002-03-01 2005-12-20 Ravgen, Inc. Rapid analysis of variations in a genome
JP4116856B2 (ja) 2002-10-02 2008-07-09 富士フイルム株式会社 1塩基多型の検出方法
EP1599608A4 (en) 2003-03-05 2007-07-18 Genetic Technologies Ltd Identification of fetal DNA and fetal cell marker in maternal plasma or serum
US20060014179A1 (en) 2004-06-02 2006-01-19 New England Biolabs, Inc. Inferring function from shotgun sequencing data
CA2584723A1 (en) 2004-10-22 2006-05-04 Redpath Integrated Pathology, Inc. Enhanced amplifiability of minute fixative-treated tissue samples, minute stained cytology samples, and other minute sources of dna
US8609338B2 (en) 2006-02-28 2013-12-17 University Of Louisville Research Foundation, Inc. Detecting fetal chromosomal abnormalities using tandem single nucleotide polymorphisms
EP2351858B1 (en) 2006-02-28 2014-12-31 University of Louisville Research Foundation Detecting fetal chromosomal abnormalities using tandem single nucleotide polymorphisms
PL2557520T3 (pl) 2007-07-23 2021-10-11 The Chinese University Of Hong Kong Określanie zaburzenia równowagi sekwencji kwasu nukleinowego
WO2009042198A1 (en) 2007-09-27 2009-04-02 Fred Hutchinson Cancer Research Center Identifying a subject with an increased risk of invasive mold infection
US8748113B2 (en) 2007-11-15 2014-06-10 The Johns Hopkins University Methods for detecting and monitoring circulating cancer stem cells
EP2364368B1 (en) 2008-11-07 2014-01-15 Sequenta, Inc. Methods of monitoring conditions by sequence analysis
WO2010087985A2 (en) 2009-01-28 2010-08-05 Yale University Novel markers for detection of complications resulting from in utero encounters
WO2011015944A2 (en) 2009-08-06 2011-02-10 Cedars-Sinai Medical Center Use of free dna as an early predictor of severity in acute pancreatitis
JP2013509883A (ja) 2009-11-06 2013-03-21 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 臓器移植患者における移植片拒絶反応の非侵襲的診断方法
US20120010085A1 (en) 2010-01-19 2012-01-12 Rava Richard P Methods for determining fraction of fetal nucleic acids in maternal samples
WO2011094646A1 (en) 2010-01-28 2011-08-04 Medical College Of Wisconsin, Inc. Methods and compositions for high yield, specific amplification
JP5842811B2 (ja) 2010-03-24 2016-01-13 凸版印刷株式会社 競合プライマーによる標的塩基配列の検出方法
US20120034603A1 (en) 2010-08-06 2012-02-09 Tandem Diagnostics, Inc. Ligation-based detection of genetic variants
US10131947B2 (en) 2011-01-25 2018-11-20 Ariosa Diagnostics, Inc. Noninvasive detection of fetal aneuploidy in egg donor pregnancies
RU2671980C2 (ru) 2011-02-09 2018-11-08 Натера, Инк. Способы неинвазивного пренатального установления плоидности
US9290815B2 (en) 2011-02-21 2016-03-22 Qiagen Gmbh Method for quantifying human DNA
WO2012122374A2 (en) 2011-03-08 2012-09-13 Children's Medical Center Corporation Non-invasive methods for diagnosing chronic organ transplant rejection
PL2791325T3 (pl) 2011-12-16 2018-08-31 Basf Agrochemical Products, B.V. Sposoby i kompozycje do analizy genów ahasl w pszenicy
US10077474B2 (en) 2012-05-29 2018-09-18 Abbott Molecular, Inc. Method of designing primers, method of detecting single nucleotide polymorphisms (SNPs), method of distinguishing SNPs, and related primers, detectable oligonucleotides, and kits
KR102082735B1 (ko) 2012-08-03 2020-02-28 훼링 비.브이. 암컷 불임에 대한 치료학적 타겟 및 진단 마커로서의 세포-유리 dna
US10988803B2 (en) 2014-12-29 2021-04-27 Life Genetics Lab, Llc Multiplexed assay for quantitating and assessing integrity of cell-free DNA in biological fluids for cancer diagnosis, prognosis and surveillance
WO2014143989A1 (en) 2013-03-15 2014-09-18 Medical College Of Wisconsin, Inc. Fetal well being surveillance using fetal specific cell free dna
GB201304810D0 (en) 2013-03-15 2013-05-01 Isis Innovation Assay
WO2014194113A2 (en) 2013-05-29 2014-12-04 Chronix Biomedical Detection and quantification of donor cell-free dna in the circulation of organ transplant recipients
IL285521B2 (en) 2013-08-19 2023-03-01 Singular Bio Inc Methods for single molecule detection
CA2922746A1 (en) 2013-09-06 2015-03-12 Immucor Gti Diagnostics, Inc. Compositions and methods for diagnosis and prediction of solid organ graft rejection
WO2015069933A1 (en) 2013-11-06 2015-05-14 The Board Of Trustees Of The Leland Stanford Junior University Circulating cell-free dna for diagnosis of transplant rejection
WO2015178978A2 (en) 2014-02-14 2015-11-26 The Board Of Regents Of The University Of Texas System Strand exchange hairpin primers that give high allelic discrimination
TR201907106T4 (tr) 2014-03-14 2019-06-21 Caredx Inc Bir transplant alıcısında immünosüpresif terapileri izleme yöntemleri.
CA2945962C (en) 2014-04-21 2023-08-29 Natera, Inc. Detecting mutations and ploidy in chromosomal segments
JP6681841B2 (ja) 2014-05-09 2020-04-15 ライフコーデックス アーゲー 特別な細胞タイプに由来するdnaの検出とそれに関連する方法
WO2016001411A1 (en) 2014-07-03 2016-01-07 Multiplicom N.V. Methods for non-invasive detection of transplant health or rejection
CN115029342B (zh) 2014-08-22 2025-04-08 分析生物科学有限公司 用于无细胞dna的定量遗传分析的方法
US10704104B2 (en) 2014-10-20 2020-07-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for screening a subject for a cancer
WO2016123698A1 (en) 2015-02-06 2016-08-11 Uti Limited Partnership Diagnostic assay for post-transplant assessment of potential rejection of donor organs
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
AU2016291558A1 (en) 2015-07-10 2018-02-08 West Virginia University Markers of stroke and stroke severity
RU2742768C2 (ru) 2015-10-22 2021-02-10 Сайтосорбентс Корпорейшн Применение многофункционального гемосовместимого пористого полимерно гранулированного сорбента для удаления гемоглобина, калия, цитокинов, биоактивных липидов и иммуноглобулинов из биологических жидкостей
AU2016363113A1 (en) 2015-12-03 2018-06-07 Alfred Health Monitoring treatment or progression of myeloma
EP3449018A4 (en) 2016-04-29 2019-11-06 The Medical College of Wisconsin, Inc. REAL-TIME PCR WITH MULTIPLEXED OPTIMIZED MISMATCH AMPLIFICATION (MOMA) FOR THE EVALUATION OF FETAL WELL-BEING
WO2017190104A1 (en) 2016-04-29 2017-11-02 Medical College Of Wisconsin, Inc. Multiplexed optimized mismatch amplification (moma)-real time pcr for assessing cancer
WO2017190106A1 (en) 2016-04-29 2017-11-02 Medical College Of Wisconsin, Inc. Multiplexed optimized mismatch amplification (moma)-target number
WO2018085597A1 (en) 2016-11-02 2018-05-11 Medical College Of Wisconsin, Inc. Methods for assessing risk using mismatch amplification and statistical methods
JP2019534016A (ja) * 2016-11-02 2019-11-28 ザ メディカル カレッジ オブ ウィスコンシン,インコーポレイテッドThe Medical College of Wisconsin, Inc. 全および特異的な無細胞dnaを使用しリスクを評価するための方法
US12447464B2 (en) 2016-12-22 2025-10-21 Duke University Polycationic microfibers and methods of using the same
US20210139988A1 (en) 2017-06-20 2021-05-13 The Medical College Of Wisconsin, Inc. Assessing conditions in transplant subjects using donor-specific cell-free dna
CA3067635A1 (en) 2017-06-20 2018-12-27 The Medical College Of Wisconsin, Inc. Transplant patient monitoring with cell-free dna
WO2019008408A1 (en) 2017-07-07 2019-01-10 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS FOR DETERMINING WHETHER A PATIENT SUFFERING FROM MYELOPROLIFERATIVE NEOPLASM IS AT RISK OF THROMBOSIS
CA3069196A1 (en) 2017-07-07 2019-01-10 Mcmaster University Risk assessment tool for patients with sepsis
WO2019053243A1 (en) 2017-09-18 2019-03-21 Santersus Sa METHOD AND DEVICE FOR PURIFYING BLOOD OF FREE CIRCULATING DNA
MA51210A (fr) 2017-12-01 2020-10-07 Juno Therapeutics Inc Procédés de dosage et de modulation de cellules génétiquement modifiées
US12084720B2 (en) 2017-12-14 2024-09-10 Natera, Inc. Assessing graft suitability for transplantation
WO2019217918A1 (en) 2018-05-10 2019-11-14 The Medical College Of Wisconsin, Inc. Multiplexed optimized mismatch amplification (moma)-cancer risk assessment with non-cancer associated targets
WO2020076957A1 (en) 2018-10-09 2020-04-16 Tai Diagnostics, Inc. Cell lysis assay for cell-free dna analysis
WO2020131955A1 (en) 2018-12-17 2020-06-25 The Medical College Of Wisconsin, Inc. Assessing risk with total cell-free dna
WO2020206269A1 (en) 2019-04-03 2020-10-08 The Medical College Of Wisconsin, Inc. Transplant patient monitoring with cell-free dna
WO2020206292A2 (en) 2019-04-03 2020-10-08 The Medical College Of Wisconsin, Inc. Assessing conditions in transplant subjects using donor-specific cell-free dna
WO2020206290A1 (en) 2019-04-03 2020-10-08 The Medical College Of Wisconsin, Inc. Methods for assessing risk using total cell-free dna

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150086477A1 (en) * 2012-04-19 2015-03-26 Medical College Of Wisconsin, Inc. Highly sensitive surveillance using detection of cell free dna
WO2016176662A1 (en) * 2015-04-30 2016-11-03 Medical College Of Wisconsin, Inc. Multiplexed optimized mismatch amplification (moma)-real time pcr for assessing cell-free dna

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Cell-Free DNA as a Noninvasive Acute Rejection Marker in Renal Transplantation", CLINICAL CHEMISTRY, vol. Volume 55, Issue 11, JPN6022011968, 2009, pages 1958 - 1966, ISSN: 0004889020 *
"Quantification of Circulating Cell-Free DNA in Pediatric Heart Transplant Recipients", THE JOURNAL OF HEART AND LUNG TRANSPLANTATION, vol. Volume 30, Issue 4, JPN6022011966, 2011, pages 139 - 407, ISSN: 0004889021 *
ACTA PAEDIATRICA, vol. 96, JPN6023027208, 2007, pages 644 - 647, ISSN: 0005100406 *
医学図書館, vol. 51, no. 4, JPN6023027207, 2004, pages 387 - 388, ISSN: 0005100405 *

Also Published As

Publication number Publication date
CN110945136A (zh) 2020-03-31
US20210139969A1 (en) 2021-05-13
EP3642353B1 (en) 2025-03-05
AU2018288832B2 (en) 2025-03-06
WO2018237075A1 (en) 2018-12-27
AU2018288832A1 (en) 2020-01-16
EP4488387A2 (en) 2025-01-08
CA3067637A1 (en) 2018-12-27
EP3642353C0 (en) 2025-03-05
EP3642353A1 (en) 2020-04-29
EP3642353A4 (en) 2021-02-24
US11773434B2 (en) 2023-10-03
IL271460A (en) 2020-01-30
AU2025204208A1 (en) 2025-06-26
US20240026437A1 (en) 2024-01-25
EP4488387A3 (en) 2025-07-23

Similar Documents

Publication Publication Date Title
US20240026437A1 (en) Assessing transplant complication risk with total cell-free dna
JP7323462B2 (ja) セルフリーdnaによる移植患者のモニタリング
US20220267849A1 (en) Transplant patient monitoring with cell-free dna
US20230167499A1 (en) Methods for assessing risk using total cell-free dna
US20220356522A1 (en) Assessing conditions in transplant subjects using donor-specific cell-free dna
EP3535413B1 (en) Methods for assessing risk using total and specific cell-free dna
US20210139988A1 (en) Assessing conditions in transplant subjects using donor-specific cell-free dna
WO2020131955A1 (en) Assessing risk with total cell-free dna
JP2019534017A (ja) ミスマッチ増幅を使用するリスクを評価するための方法および統計方法
HK40029115A (en) Assessing transplant complication risk with total cell-free dna
HK40029115B (en) Assessing transplant complication risk with total cell-free dna

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210621

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220328

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220330

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221223

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230405

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230705